The Amyotrophic Lateral Sclerosis (ALS) Market Forecast to grow at a CAGR of more than 5.5% : Visiongain Research Ltd.
28 mai 2021 09h00 HE
|
Visiongain Ltd
Visiongain has launched a Amyotrophic Lateral Sclerosis (ALS) Market Report 2020-2030, by Treatment (Medication, Stem Cell Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail...
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
17 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
AB Science annonce qu'une publication indépendante confirme le rôle du masitinib comme thérapie potentielle dans les troubles neurodégénératifs, y compris la maladie d'Alzheimer
08 mars 2021 02h02 HE
|
AB Science
COMMUNIQUE DE PRESSE UNE NOUVELLE PUBLICATION INDÉPENDANTE DANS LA REVUE INTERNATIONALE...
AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer's Disease
08 mars 2021 02h02 HE
|
AB Science
PRESS RELEASE NEW INDEPENDENT PUBLICATION IN THE INTERNATIONAL JOURNAL OF...
Recent Analysis on Amyotrophic Lateral Sclerosis Clinical Trials
22 févr. 2021 20h30 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Recent Analysis on Amyotrophic Lateral Sclerosis Clinical Trials DelveInsight reports a complete review on Current and Emerging Therapies in...
AB Science tiendra une conférence virtuelle le 17 décembre 2020 sur les résultats du masitinib dans la maladie d'Alzheimer
16 déc. 2020 11h55 HE
|
AB Science
AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE SUR LES RESULTATS DU MASITINIB DANS LA MALADIE D’ALZHEIMER LE JEUDI 17 DECEMBRE 2020 Paris, 16 décembre 2020, 18h AB Science SA (NYSE Euronext -...
AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
16 déc. 2020 11h55 HE
|
AB Science
AB SCIENCE WILL HOST A LIVE WEBCAST ON THURSDAY DECEMBER 17, 2020 ON MASITINIB RESULTS IN ALZHEIMER’S DISEASE Paris, December 16, 2020, 6pm CET AB Science SA (NYSE Euronext –...
AB Science annonce que l'étude de phase 2B/3 évaluant le masitinib dans la maladie d'Alzheimer a atteint son critère d'évaluation principal
16 déc. 2020 01h53 HE
|
AB Science
L'ÉTUDE DE PHASE 2B/3 ÉVALUANT LE MASITINIB DANS LA MALADIE D'ALZHEIMER A ATTEINT SON OBJECTIF PRINCIPAL LE MASITINIB A EU UN EFFET SIGNIFICATIF SUR LA COGNITION, MESURÉE AVEC L'ADAS-COG, ET SUR...
AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpoint
16 déc. 2020 01h53 HE
|
AB Science
PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASE MET ITS PRIMARY ENDPOINT MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY,...
EIB supports AB Science in its COVID-19 development programme
30 nov. 2020 00h56 HE
|
AB Science
Paris, 30 November 2020, 7am EIB supports AB Science in its COVID-19 development programme Financing deal worth €15.0 million signed to support clinical development programme for masitinibMasitinib...